Comunicados de prensa

Encuentre cualquiera de nuestros más recientes comunicados de prensa, manténgase actualizado con las últimas noticias e infórmese sobre los próximos eventos a los que acudirá Curium.

26th mayo 2023

Curium receives positive CHMP opinion of PYLCLARI® for primary staging of patients with high-risk PCa prior to initial curative therapy and to localize recurrence of PCa in patients with a suspected recurrence based on increasing serum Prostate-Specific Antigen (PSA) levels after primary treatment with curative intent

23rd mayo 2023

Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T

2nd mayo 2023

Curasight and Curium announce global partnership for uTRACE® in prostate cancer

14th marzo 2023

Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial

2nd marzo 2023

Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO

21st diciembre 2022

Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99

24th noviembre 2022

Curium’s Customers to benefit from Mo-99 Production restart

22nd noviembre 2022

Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.

9th noviembre 2022

Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients

18th agosto 2022

NRG and Curium Sign Multi-Year Isotope Production Contract

27th junio 2022

Curium Announces The Submission Of Its Marketing Authorization Application For [¹⁸F]-DCFPyL To The European Medicines Agency

12th mayo 2022

Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial

3rd mayo 2022

Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients

19th abril 2022

Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

5th abril 2022

Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.

25th enero 2022

Curium to become major player in the supply on non carrier added Lu-177

15th diciembre 2021

Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer

27th octubre 2021

Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T

24th agosto 2021

Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T

1st junio 2021

FILTRAR POR

Comunicados de prensa

Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T

Curasight and Curium announce global partnership for uTRACE® in prostate cancer

Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial

Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO

Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99

Curium’s Customers to benefit from Mo-99 Production restart

Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.

Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients

NRG and Curium Sign Multi-Year Isotope Production Contract

Curium Announces The Submission Of Its Marketing Authorization Application For [¹⁸F]-DCFPyL To The European Medicines Agency

Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial

Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients

Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.

Curium to become major player in the supply on non carrier added Lu-177

Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer

Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T

Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T

Curium Acquires Austrian Radiopharmaceuticals Company IASON

FILTRAR POR

Comunicados de prensa

Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T

Curasight and Curium announce global partnership for uTRACE® in prostate cancer

Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial

Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO

Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99

Curium’s Customers to benefit from Mo-99 Production restart

Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.

Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients

NRG and Curium Sign Multi-Year Isotope Production Contract

Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency

Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial

Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients

Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.

Curium to become major player in the supply on non carrier added Lu-177

Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer

Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T

Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T

Curium Acquires Austrian Radiopharmaceuticals Company IASON

Curium Announces The Submission Of Its Marketing Authorization Application For [¹⁸F]-DCFPyL To The European Medicines Agency